Abstract

BackgroundAlthough psychiatric disorders are frequently characterized by clinical heterogeneity, high recurrence, and unpredictable prognosis, studies of mRNA expression variations in blood cells from psychiatric patients constitute a promising avenue to establish clinical biomarkers. We report here, to our knowledge, the first genetic monitoring of a major depressive episode (MDE).Case presentationThe subject is a 51-year-old male, who was healthy at baseline and whose blood mRNA was monitored over 67 weeks for expression variations of 9 candidate genes. At week 20 the subject experienced a mild to moderate unexpected MDE, and oral antidepressant treatment was initiated at week 29. At week 36, the patient recovered from his MDE. After 6 months, antidepressant treatment was discontinued and the subject remained free of depressive symptoms. Genetic monitoring revealed that mRNA expression of SLC6A4/5HTT increased with the emergence of a depressive state, which later returned to basal levels after antidepressant treatment and during MDE recovery. PDLIM5, S100A10 and TNF mRNA showed also an interesting pattern of expression with regards to MDE evolution.ConclusionThis case demonstrated the applicability of peripheral mRNA expression as a way to monitor the natural history of MDE.

Highlights

  • Psychiatric disorders are frequently characterized by clinical heterogeneity, high recurrence, and unpredictable prognosis, studies of mRNA expression variations in blood cells from psychiatric patients constitute a promising avenue to establish clinical biomarkers

  • We previously tested mRNA expression variations in blood samples from individuals suffering from severe major depressive episode (MDE), with the aim of validating gene candidates proposed by others as biomarkers in major depression [6]

  • We describe the variation of mRNA expression levels of selected candidate genes associated with mood disorders in a single subject, who was recruited by chance, before, during and after a first MDE

Read more

Summary

Introduction

Psychiatric disorders are frequently characterized by clinical heterogeneity, high recurrence, and unpredictable prognosis, studies of mRNA expression variations in blood cells from psychiatric patients constitute a promising avenue to establish clinical biomarkers. Several investigators have reported variations in mRNA levels between patients and control subjects based on peripheral and accessible tissues and between preand post-treatment conditions in major depressive disorder (MDD) and bipolar disorder (BD) [5,6,7,8,9,10,11]. Bd Pierre Dramard, 13344 cedex 15 Marseille, France 3FondaMental, Fondation de Recherche et de Soins en Santé Mentale, Créteil, France Full list of author information is available at the end of the article affordable costs [12].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call